Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities

Publication type:
Journal article
Metadata:
Autoren
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000767185600003&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1016/j.semcancer.2020.01.015
eISSN
1096-3650
Externe Identifier
  • Clarivate Analytics Document Solution ID: ZQ6AN
  • PubMed Identifier: 32027979
ISSN
1044-579X
Zeitschrift
SEMINARS IN CANCER BIOLOGY
Schlüsselwörter
  • Boswellia
  • Burseraceae
  • Clinical trials
  • Pharmacology
  • Signaling pathways
  • Toxicology
Paginierung
39 - 57
Datum der Veröffentlichung
2022
Status
Published
Titel
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities
Sub types
  • Article
Ausgabe der Zeitschrift
80

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
DOI
10.1016/j.semcancer.2020.01.015
ISSN
1044-579X
Zeitschrift
Seminars in Cancer Biology
Sprache
en
Paginierung
39 - 57
Datum der Veröffentlichung
2022
Status
Published
Herausgeber
Elsevier BV
Herausgeber URL
http://dx.doi.org/10.1016/j.semcancer.2020.01.015
Datum der Datenerfassung
2022
Titel
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities
Ausgabe der Zeitschrift
80

Data source: Crossref

Abstract
The oleogum resins of Boswellia species known as frankincense have been used for ages in traditional medicine in India, China and the Arabian world independent of its use for cultural and religious rituals in Europe. During the past two decades, scientific investigations provided mounting evidence for the therapeutic potential of frankincense. We conducted a systematic review on the anti-inflammatory and anti-cancer activities of Boswellia species and their chemical ingredients (e.g. 3-O-acetyl-11-keto-β boswellic acid, α- and β-boswellic acids, 11-keto-β-boswellic acid and other boswellic acids, lupeolic acids, incensole, cembrenes, triterpenediol, tirucallic acids, and olibanumols). Frankincense acts by multiple mechanisms, e.g. by the inhibition of leukotriene synthesis, of cyclooxygenase 1/2 and 5-lipoxygenase, of oxidative stress, and by regulation of immune cells from the innate and acquired immune systems. Furthermore, frankincense modulates signaling transduction responsible for cell cycle arrest and inhibition of proliferation, angiogenesis, invasion and metastasis. Clinical trials showed the efficacy of frankincense and its phytochemicals against osteoarthritis, multiple sclerosis, asthma, psoriasis and erythematous eczema, plaque-induced gingivitis and pain. Frankincense revealed beneficial effects towards brain tumor-related edema, but did not reduce glioma size. Even if there is no treatment effect on brain tumors itself, the management of glioma-associated edema may represent a desirable improvement. The therapeutic potential against other tumor types is still speculative. Experimental toxicology and clinical trials revealed only mild adverse side effects. More randomized clinical trials are required to estimate the full clinical potential of frankincense for cancer therapy.
Addresses
  • Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany. Electronic address: efferth@uni-mainz.de.
Autoren
DOI
10.1016/j.semcancer.2020.01.015
eISSN
1096-3650
Externe Identifier
  • PubMed Identifier: 32027979
Funding acknowledgements
  • Johannes Gutenberg-Universität Mainz:
Open access
false
ISSN
1044-579X
Zeitschrift
Seminars in cancer biology
Schlüsselwörter
  • Humans
  • Boswellia
  • Glioma
  • Resins, Plant
  • Anti-Inflammatory Agents
  • Immunologic Factors
  • Frankincense
Sprache
eng
Medium
Print-Electronic
Online publication date
2020
Paginierung
39 - 57
Datum der Veröffentlichung
2022
Status
Published
Datum der Datenerfassung
2020
Titel
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities.
Sub types
  • Systematic Review
  • Review
  • Journal Article
Ausgabe der Zeitschrift
80

Data source: Europe PubMed Central

Abstract
The oleogum resins of Boswellia species known as frankincense have been used for ages in traditional medicine in India, China and the Arabian world independent of its use for cultural and religious rituals in Europe. During the past two decades, scientific investigations provided mounting evidence for the therapeutic potential of frankincense. We conducted a systematic review on the anti-inflammatory and anti-cancer activities of Boswellia species and their chemical ingredients (e.g. 3-O-acetyl-11-keto-β boswellic acid, α- and β-boswellic acids, 11-keto-β-boswellic acid and other boswellic acids, lupeolic acids, incensole, cembrenes, triterpenediol, tirucallic acids, and olibanumols). Frankincense acts by multiple mechanisms, e.g. by the inhibition of leukotriene synthesis, of cyclooxygenase 1/2 and 5-lipoxygenase, of oxidative stress, and by regulation of immune cells from the innate and acquired immune systems. Furthermore, frankincense modulates signaling transduction responsible for cell cycle arrest and inhibition of proliferation, angiogenesis, invasion and metastasis. Clinical trials showed the efficacy of frankincense and its phytochemicals against osteoarthritis, multiple sclerosis, asthma, psoriasis and erythematous eczema, plaque-induced gingivitis and pain. Frankincense revealed beneficial effects towards brain tumor-related edema, but did not reduce glioma size. Even if there is no treatment effect on brain tumors itself, the management of glioma-associated edema may represent a desirable improvement. The therapeutic potential against other tumor types is still speculative. Experimental toxicology and clinical trials revealed only mild adverse side effects. More randomized clinical trials are required to estimate the full clinical potential of frankincense for cancer therapy.
Date of acceptance
2020
Autoren
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/32027979
DOI
10.1016/j.semcancer.2020.01.015
eISSN
1096-3650
Zeitschrift
Semin Cancer Biol
Schlüsselwörter
  • Boswellia
  • Burseraceae
  • Clinical trials
  • Pharmacology
  • Signaling pathways
  • Toxicology
  • Anti-Inflammatory Agents
  • Boswellia
  • Frankincense
  • Glioma
  • Humans
  • Immunologic Factors
  • Resins, Plant
Sprache
eng
Country
England
Paginierung
39 - 57
PII
S1044-579X(20)30034-1
Datum der Veröffentlichung
2022
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2022
Titel
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities.
Sub types
  • Journal Article
  • Review
  • Systematic Review
Ausgabe der Zeitschrift
80

Data source: PubMed

Beziehungen:
Property of

Tools